(Q28167713)

English

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness

scientific article (publication date: March 2004)

In more languages

edit

Statements

0 references

1 reference

Europe PubMed Central

title

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness (English)

0 references

1 reference

1 reference

1 reference

coronary artery disease

1 reference

Graeme J Hankey

2

0 references

John W. Eikelboom

series ordinal

3

object named as

John W Eikelboom

0 references

Wai Khoon Ho

series ordinal

1

object named as

Wai Khoon Ho

0 references

language of work or name

English

0 references

publication date

March 2004

0 references

published in

Expert Opinion on Pharmacotherapy

0 references

volume

5

0 references

issue

3

0 references

page(s)

493-503

0 references

cites work

Direct medical costs of coronary artery disease in the United States.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Incidence of myocardial infarction in the Danish MONICA population 1982-1991.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Mortality by cause for eight regions of the world: Global Burden of Disease Study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

A concise review of the cost-effectiveness of coronary heart disease prevention

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.3.493

retrieved

21 January 2018

Identifiers

DOI

10.1517/EOPH.5.3.493.27372

0 references

10.1517/14656566.5.3.493

0 references

PubMed publication ID

15013918

0 references

(Q28167713)

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)